<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000657.v1.p1" parentStudy="phs000657.v1.p1" createDate="2013-08-26" modDate="2013-09-04">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Glen Weiss, MD</td><td>Translational Genomics Research Institute, Phoenix, AZ, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Winnie Liang, PhD</td><td>Translational Genomics Research Institute, Phoenix, AZ, USA</td></tr>
		<tr><td>Co-Investigator</td><td>John D. Carpten, PhD</td><td>Translational Genomics Research Institute, Phoenix, AZ, USA</td></tr>
		<tr><td>Co-Investigator</td><td>David W. Craig, PhD</td><td>Translational Genomics Research Institute, Phoenix, AZ, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Daniel D. Von Hoff, MD</td><td>Translational Genomics Research Institute, Phoenix, AZ, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>NGS in Advanced Cancers</StudyNameEntrez>
	<StudyNameReportPage>A Pilot Study Using Next Generation Sequencing in Advanced Cancers: Feasibility and Challenges</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>In this study, we used NGS to identify somatic events in advanced stage cancer patients to demonstrate the feasibility for using this approach to improve patient treatment.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, 			Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW." title="A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and Challenges." journal="PLoS ONE, accepted"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Carcinoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Glen Weiss, MD</AttName>
			<Institution>Translational Genomics Research Institute, Phoenix, AZ, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Winnie Liang, PhD</AttName>
			<Institution>Translational Genomics Research Institute, Phoenix, AZ, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>John D. Carpten, PhD</AttName>
			<Institution>Translational Genomics Research Institute, Phoenix, AZ, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>David W. Craig, PhD</AttName>
			<Institution>Translational Genomics Research Institute, Phoenix, AZ, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Daniel D. Von Hoff, MD</AttName>
			<Institution>Translational Genomics Research Institute, Phoenix, AZ, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>To participate, patients must have been age &#8805; 18 and willing to undergo a biopsy or surgical procedure to obtain tissue, unless a frozen tumor collected less than 8 weeks prior was available. Interested participants were made aware that obtaining a new biopsy may not be a part of the patient&#39;s routine care for their malignancy. Other eligibility criteria included: baseline laboratory data indicating acceptable bone marrow reserve, liver, and renal function, Karnofsky performance status &#8805; 80%, and life expectancy &#62; 3 months. Participation on another clinical trial involving treatment prior to or during participation on this study was allowed. Main exclusion criteria were symptomatic or untreated central nervous system (CNS) metastases, known active infections requiring intravenous antimicrobial therapy, known HBV, HCV, or HCV infection(s) requiring antiviral therapy, pregnant or breast feeding women, or tumor that was inaccessible for a biopsy.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-MDS" longName="General Research Use (MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000657.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000657.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000657.v1.p1" FileName="eNCI_0176_DUC_7.29.2013.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (MDS)</ConsentName>
        <ConsentAbbrev>GRU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification. Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
